NCT06096714 is a EARLY_PHASE1 clinical trial of Nicotine in Smoking Addiction, sponsored by Yale University.

Who is sponsoring NCT06096714?

NCT06096714 is sponsored by Yale University.

What drugs are being tested in NCT06096714?

Interventions in NCT06096714: Nicotine, Saline.

What condition does NCT06096714 study?

NCT06096714 studies Smoking Addiction.

Is NCT06096714 still recruiting?

NCT06096714 is currently recruiting now. Last updated 11 April 2025.

Last reviewed 2025-04-11 · How we verify

NCT06096714

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Addictive Threshold of Nicotine

Recruiting now EARLY_PHASE1 Last updated 11 April 2025

What this trial tests

EARLY_PHASE1 trial testing Nicotine in Smoking Addiction in 36 participants. Currently enrolling.

Timeline

27 February 2024

Primary endpoint
30 January 2027

30 January 2027

Quick facts

Lead sponsor	Yale University
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	health services research
Enrollment	36
Start date	27 February 2024
Primary completion	30 January 2027
Estimated completion	30 January 2027
Sites	1 location across United States

Drugs / interventions tested

Nicotine (NICOTINE) — full drug profile →
Saline

Conditions studied

Smoking Addiction — all drugs for Smoking Addiction →

Sponsor

Yale University

Who can join

Adults 21 to 59, any sex, with Smoking Addiction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the nicotine threshold dose(s) for discrimination, subjective-rewarding effects, -and reinforcement in smokers with different levels of dependence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Nicotine

Trials testing the same drug.

NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
NCT06027723 — Nicotine and Pavlovian Bias · EARLY_PHASE1 · unknown
NCT03634839 — Effects of E-cigarette Flavors on Youth TCORS 2.0 · Phase 1 · completed
NCT05335915 — Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers · Phase 1 · completed

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06096714 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 11 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing